Cincinnati-based Blue Water Vaccines, Inc., announced that the Company is accelerating the development of a new vaccine candidate to combat the potential pandemic influenza strain, G4 EA H1N1, which is similar to the 2009 A(H1N1)pdm09 swine flu, which was extremely lethal.
This universal influenza vaccine candidate provides protection from H1, H3, and Flu B.
The Company has completed the initial design and in vivo analysis of the H1 vaccine candidate design. The H3 and Flu B constructs are entering into the final in vivo stage of testing prior to moving the universal program into manufacturing.
Joseph Hernandez, Chairman, and CEO of Blue Water Vaccines stated in a press release issued on October 29, 2020: "Our H1 construct has shown significant in vivo cross-reactivity with all previous pandemic strains, including the 1918 H1N1 and 2009 pandemic H1N1, and produces neutralizing antibodies in animal challenge studies."